Novartis Claim Tasigna Can Help Parkinson's Patients is Met With Skepticism

Given the fraud and deception that Novartis has admitted to in the past, it is hard to take any medical breakthrough the company claims seriously

Thursday, April 4, 2019 - The medical community is falling all over themselves in anticipation of phase 2 trials of anti-cancer chemotherapy drug Tasigna's new use for treatment of Parkinson's disease. Tasigna is suspected of being able to trigger the production of dopamine in Parkinson's sufferers, reduce inflation, and lessen the disease's symptoms. Parkinson's News Today reports, "Treatment with a single dose of the leukemia therapy Tasigna (nilotinib) improves the brain's ability to use dopamine in people with Parkinson's by reducing inflammation and levels of toxic alpha-synuclein, according to Phase 2 trial results." In addition, earlier studies of Tasigna's effect on Parkinson's disease conducted at Georgetown University hospital found "that a low dose of Novartis' Tasigna is able to reach the brain, ease inflammation and degrade misfolded alpha-synuclein - the main component of Parkinson's characteristic Lewy bodies - in animal models of neurodegenerative disease. Tasigna also increased levels of dopamine - the neurotransmitter found at reduced levels in this disease - and improved motor and cognitive function." National Tasigna lawyers representing families and individuals in the United States are offering a free consultation and no obligation.

People should be skeptical of Tasigna's newly-found ability to treat multiple diseases. The drug's maker, Novartis, has a long history of bending the rules and throwing caution to the wind if it means selling a greater volume of drugs. The latest farce Novartis is attempting to pull on an unsuspecting medical community is for doctors to add Tasigna to the list of drugs that they prescribe, not only treat cancer, but also treat Parkinson's disease. Nowhere is the company's checkered past mentioned nor the crimes they have committed. In 2015, Novartis settled a $1 billion fine levied on them by the US Department of Justice (DOJ) for running an illegal bribery and kickback scheme in collusion with certain specialty pharmacies. In prosecuting the charges, the DOJ categorized Novartis as "repeat offenders." In 2010, the company violated the False Claims Act and plead guilty to 'misdemeanor criminal allegations involving off-label promotion and kickbacks to doctors," and was fined for $422.5 million.

In addition to Novartis track record of deception, doctors prescribing Tasigna to treat Parkinson's disease in the future may be unaware of drug's side effect of causing atherosclerosis, a hardening, and thickening of the body's major arteries and the potential to cause a stroke or a heart attack. Tasigna is very, very effective in killing cells, cancer cells, and healthy cells. Tasigna causes the delicate and smooth inner lining of the major arteries leading to and from the lungs, brain, and heart to become rough, preventing the blood from flowing smoothly as the body intended. The irritated inner arterial walls will then rapidly catch fatty blood platelets that accumulate and lessen the volume of blood that can pass through them. Atherosclerosis as this condition is called can lead to inadequate blood getting to the extremities of the toes and feet, cause tissue death, and require amputation.

More Recent Tasigna Atherosclerosis Lawsuit News:

• Tasigna Patients Are Warned of The Risk of Sudden Death | 5/13/2019
• Tasigna's Atherosclerosis Risk Is Well-Documented By Researchers For Peer-Reviewed Medical Publications | 5/8/2019
• Tasigna's Atherosclerosis Side Effect Is Not Forgotten | 4/17/2019
• Trying Tasigna As A Last Resort May Make Sense To Terminally Ill Cancer Patients | 4/12/2019
• Novartis Failed To Warn American Doctors Who In Turn Failed To Warn Patients of Tasigna's Atherosclerosis Risks | 3/20/2019
• Tasigna Is Being Repurposed To Treat Parkinson's Disease | 3/14/2019
• Some Patient Can Cease Taking Tasigna But They May Have Already Developed Atherosclerosis | 3/12/2019
• Health Experts Warn of Potentially Deadly Tasigna Drug Interactions | 3/5/2019
• The Potential To Someday Stop Tasigna Treatments Should Not Be An Incentive To Take The Drug | 2/28/2019
• Tasigna Studies Show The Drug Should Be Taken As A Last Resort | 2/24/2019
• Cancer Doctors and Medical Websites Should Take Tasigna's Atherosclerosis Risks More Seriously | 2/18/2019
• The FDA May Be Putting Children's Lives In Danger By Ignoring Tasigna's Atherosclerosis Risk | 2/12/2019
• The FDA May Have Overlooked Tasigna's Atherosclerosis Side Effect When Approving its Usage by Children | 2/5/2019
• Children With Cancer May Now Start Taking Tasigna | 1/31/2019
• Studies Reported by Leading Experts Focus on Tasigna Toxicity | 1/25/2019
• Novartis Has a History of Deceptive Sale Practices That Taints Their Credibility | 1/22/2019
• Novartis Changes Tasigna's Label But Not Its Toxicity | 1/16/2019
• Tasigna Doctors May Be Ignoring Atherosclerosis Risks | 1/11/2019
• Cancer Doctors Prescribing Tasigna Should Be Trained Like Heart Specialists | 1/8/2019
• Tasigna is Effective in Treating Chronic Myeloid Leukemia | 1/1/2019
• Early Warning Signs of Chronic Myeloid Leukemia (CML) | 12/5/2018
• CML Patients in Remission May Discontinue Taking Tasigna | 12/1/2018
• Tasigna's Atherosclerosis Warnings is Rarely Seen by Cancer Patients | 11/28/2018
• Novartis' Failure to Warn the FDA May Have Led to Atherosclerosis in As Many As One in Four Tasigna Patients | 11/12/2018
• Novartis Highlights Tasigna's Effectiveness yet Downplays The Drug's Deadly Side Effects | 11/8/2018
• Novartis Takes Advantage of Tasigna's Catch 22 | 10/30/2018
• Tasigna Atherosclerosis Ignored by Novartis Celebrity Spokesperson | 10/24/2018
• Oncologists May Be Ignoring the Cardiovascular Side Effects of Tasigna | 10/16/2018
• The FDA Atherosclerosis Warning Came Too Late for Tasigna Patients in the United States | 10/8/2018
• One-Third of Tasigna Patients Could Face Coronary Bypass Surgery | 10/4/2018
• Billion Dollar Fines Are Just a Cost of Doing Business For Novartis | 10/2/2018
• Cancer Patients Should View Novartis' New Tasigna Label With Scepticism | 9/28/2018
• Novartis Boasts of Tasigna's Effectiveness While Ignoring the Atherosclerosis Side Effects | 9/27/2018
• Tasigna May Be One Of The Most Deadly Drugs On The Market Today | 9/25/2018
• NBA Star's Arterial Blockage May Have Been Caused by Taking Tasigna | 9/22/2018
• Taxpayers Saved Billions By Novartis AG Whistleblower | 9/20/2018
• Tasigna Carries The Unacceptable Risk of Developing Atherosclerosis and Amputation | 9/19/2018
• Tasigna's Cancer-Fighting Success May Be Tempered By The Risk Of Sudden Death | 9/17/2018
• Novartis Pulled No Punches In Warning Canadians About The Atherosclerosis Related Side effects Of Tasigna Yet Said Nothing To Warn Cancer Patients In The United States. | 9/11/2018
• Novartis is a Repeat Offender for Fraudulent Drug Marketing | 8/29/2018
• Peripheral Artery Disease Plagues Tasigna Patients | 8/27/2018
• Patients Could Have Benefited From Gleevec's Generic Alternative | 8/21/2018
• Novartis/Tasigna Lawsuit May Seek Punitive Damages | 8/17/2018
• Tasigna Atherosclerosis Trial Set to Proceed | 8/14/2018
• Medical Websites Ignore Tasigna's Risks | 8/10/2018
• Novartis haste in rushing Tasigna to market has cost patients their lives | 8/8/2018
• Tasigna's Side Effects Require Special Attention From Prospective Patients | 8/6/2018
• Novartis Whistleblower Receives $12 Million For His Efforts | 7/31/2018
• Tasigna Atherosclerosis Hidden From Americans | 7/30/2018
• Gleevec Was a Cancer-Curing Miracle Drug | 7/26/2018
• Tasigna Stroke Victim's Trial to Proceed in Florida | 7/24/2018
• Novartis Employee Blows Whistle on Tasigna Fraud and Others | 7/20/2018
• Tasigna Side Effects Are Worse Than Cancer | 7/18/2018
• Tasigna Cancer Medication Carries More Risks Than Others | 7/11/2018
• Specialty Pharmacists Bribed to Prescribe Tasigna | 7/6/2018
• Novartis Billion-Dollar Fine for Fraudulent Marketing Tactics | 7/2/2018
• Tasigna Black Box Warning Addendum | 6/29/2018
• Tasigna Replaced Gleevec and Patients Suffered | 6/25/2018
• Specialty Pharmacists Selling Tasigna Compromised Ethical Standards | 6/20/2018
• US Department of Justice Fines Novartis One Billion Dollars | 6/13/2018
• Tasigna Sudden Death Warning | 6/11/2018
• Tasigna Cancer Treatment Poses Scary Risks | 6/7/2018
• Novartis Fraudulent Marketing Deception | 5/29/2018
• Tasigna Atherosclerosis Warning Never Made it to the US | 5/25/2018
• Novartis Tasigna Anti-Cancer Drug Has Side Effects That Include Sudden Death | 5/22/2018
• Tasigna Replaced Gleevec Under Fraudulent Circumstance | 5/18/2018
• Novartis Held Accountable For Concealing Tasigna Atherosclerosis Risk | 5/15/2018
• Tasigna Chemotherapy Carries a Sudden Death Warning | 5/10/2018
• Novartis Warns That Tasigna Can Cause Atherosclerosis | 5/6/2018
• Tasigna Poses Atherosclerosis Amputations Risk | 5/3/2018
• Tasigna Rushed to Market to Replace Gleevec | 12/29/2017
• Whistleblower Saves American Taxpayers Millions | 12/22/2017
• Gleevec-the Novartis AG Wonder Drug | 12/20/2017
• Tasigna Warnings | 12/18/2017
• Tasignas Black Box Warning Links The Drug To Atherosclerosis | 12/15/2017
• Novartis Fails To Warn The U.S. Medical Community About The Side Effects of Tasigna | 12/11/2017
• Tasigna Replaces Gleevec as the Novartis AGs Signature Anti-Cancer Chemotherapy Drug | 12/6/2017
• The Unmistakable Signs of Peripheral Artery Disease | 12/1/2017
• Whistleblower Causes Public Alert to Tasigna Side Effects | 11/27/2017
• The Estate of a California Man is Suing Novartis | 11/20/2017
• Ex-Novartis Salesmanager Blows The Whistle On Illegal Drug Marketing | 11/13/2017
• U.S. Cancer Patients Receive Tasigna Atherosclerosis Warning | 11/6/2017
• Novartis Marketed Tasigna to Replace Gleevec | 11/3/2017
• Leukemia Patients May Suffer From Heart Disease as Well | 10/30/2017
• Novartis' Potentially Misleading Drug Marketing Campaign | 10/23/2017
• Health Canada Issued a Tasigna Health Warning In 2013 | 10/16/2017
• Lawsuits Allege Novartis Was Aware of The Side Effects of Tasigna Yet Failed to Warn The American Public | 10/9/2017
• Tasigna Chemotherapy Atherosclerosis-related Side Effects | 10/2/2017
• The Onder Law Firm Seeks to Hold Novartis Accountable for the Suffering Tasigna Has Caused Families | 9/29/2017
• Novartis Fails to Warn About Tasigna Atherosclerosis | 9/22/2017
• Side Effects of Tasigna Cancer Drug Include Atherosclerosis and Peripheral Artery Disease | 9/15/2017
• Novartis Put Profits Ahead of Patients | 9/7/2017
• Novartis Failed to Warn the American Medical Community of the Side Effects of Tasigna | 9/1/2017
• Atherosclerosis Linked to Tasigna Anti Cancer Drug | 8/18/2017
• You Can Sue Novartis If You Have Developed Atherosclerosis-Related Conditions After Taking Tasigna | 8/11/2017
• Who Can Be Considered A Tasigna Victim | 8/4/2017
• Novartis AG makers of Tasigna Failed to Warn Public of the Dangerous Side Effects | 7/14/2017
• Tasigna Anti Cancer Drug Lawsuit | 7/7/2017
• Tasigna Drug Warning for Peripheral Arterial Disease | 6/30/2017
• Tasigna Cancer Treatment Drug Lawsuit | 6/26/2017
• Novartis International AG Lawsuits | 6/23/2017
• Lawsuits Against Novartis International AG Makers of Tasigna | 6/21/2017
• Tasigna Peripheral Artery Disease Warning | 6/19/2017
• Tasigna Lawsuits Against Drug Makers Novartis | 6/16/2017
• Atherosclerosis of the Aorta Linked to Tasigna Anti-Cancer Drug | 6/12/2017
• Makers of Tasigna Leukemia Drug Lawsuit | 6/9/2017
• Tasigna a Cancer Drug Treatment | 6/5/2017
• Tasigna Peripheral Arterial Disease | 6/1/2017

No-Cost, No-Obligation Tasigna Lawsuit Case Review If You or a Loved One Suffered from Tasigna Complications

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.